Brain metastases

Initiatief: NVN Aantal modules: 24

Brain metastases - Systemic therapy with symptomatic brain


What is the role of systemic therapy of symptomatic brain metastases (chemotherapy, hormonal therapy, tyrosine kinase inhibitors and other (new) drugs)?

• what are the indications?

• which interactions are possible for radiotherapy and radiosurgery?

• what are the cerebral side effects?



Non-small cell lung carcinoma (NSCLC)
Systemic therapy is generally not the treatment modality of choice for symptomatic brain metastases from NSCLC.

If chemotherapy is applied to treat symptomatic brain metastases from NSCLC, provision of radiotherapy may be delayed and only administered if there is no response to chemotherapy.

Small cell lung carcinoma (SCLC)
Patients with SCLC who present with symptomatic brain metastases are preferably treated with systemic chemotherapy and WBRT.

Breast carcinoma
The treatment of choice with brain metastases from breast carcinoma is local (radiotherapy and/or surgery).

If systemic treatment is applied, however, the choice of specific schedules of systemic therapy should depend on previously administered systemic treatment and on tumour characteristics and not on the presence of brain metastases.

After local treatment of brain metastases in patients with HER2/neu positive breast carcinoma, treatment with trastuzumab (possibly in combination with chemotherapy) may be continued upon systemic response.

Systemic therapy as primary treatment modality in patients with symptomatic brain metastases from melanoma is advised against.

Germ cell tumours
The treatment of patients with brain metastases from germ cell tumours should be performed in a specialised centre. Primary resection is generally indicated in patients with large, symptomatic brain metastases. Other patients are usually treated with standard platinum-containing chemotherapy. Local treatment may subsequently still be performed (surgery, SRS or WBRT) in case of incomplete remission.

Given the good chance of curation in this group of patients, the possible long-term neurocognitive damage must be taken into account when determining the fractionation of the radiotherapy.

Other tumour types
The guideline development group is of the opinion that the decision whether or not to use systemic therapy for treating brain metastases from other tumours than those outlined above should be made on an individual basis.

Combination therapy
Concurrent treatment with systemic therapy (chemotherapy or other radiosensitisers) and radiotherapy for brain metastases is not recommended.


Non- small cell lung carcinoma (NSCLC)
The majority of patients in the study by Robinet were, in the end, treated with WBRT and it is therefore general practice that patients with symptomatic brain metastases of NSCLC are treated with WBRT. On the basis of the study by Robinet, there are no overriding arguments to deviate from this practice.

Small cell lung carcinoma (SCLC)
Although the follow-up is rather short in the mentioned studies, there are no arguments against administering palliative WBRT simultaneously with the chemotherapy commonly provided for SCLC.

Breast carcinoma
The effectiveness of treating brain metastases from breast carcinoma with chemotherapy only has not been extensively studied. In practice, local treatment is almost always administered (surgery, SRS and/or WBRT).

Combination therapy
No conclusion can be drawn about the effect of adding chemotherapeutic agents other than temozolomide to radiotherapy. The effectiveness of non-chemotherapy radiosensitising agents added to WBRT has not been demonstrated.


Non-small cell lung carcinoma (NSCLC)
Level 2
It is plausible that, for patients receiving systemic treatment for brain metastases from NSCLC who have not been treated previously with chemotherapy, the intracranial response (27-28%), is comparable to the extracranial response.
A2: Robinet, 2001 (3)
B: Lee, 2008 (2)

Level 2
It is plausible that the timing of WBRT in patients with brain metastases from NSCLC, when systemic chemotherapy is also provided, does not influence the progression-free or total survival.
A2: Robinet, 2001 (3)
B: Lee, 2008 (2)

Small cell lung carcinoma (SCLC)
Level 3
There are indications that simultaneous treatment of patients with chemotherapy and radiotherapy (WBRT) leads to a better response and a longer time to progression of the brain metastases than chemotherapy with delayed radiotherapy. No extra neurological toxicity was observed.
A2: Postmus, 2000 (11)

Breast carcinoma
Level 3
There are indications that systemic chemotherapy in breast carcinoma patients with brain metastases may lead to an intracranial response of 30-60%.
C: Boogerd, 1992 (12);Colleoni, 1997 (13);Franciosi, 1999 (14)

Level 4
There are indications that, after local treatment of brain metastases, patients with HER2/neu positive breast carcinoma may have a prolonged and progression-free survival if treatment with trastuzumab (and chemotherapy) is continued.
D: Opinion of the development group, supported by literature (Church, 2008 (17);Bartsch, 2007 (18))

Level 3
There are indications that temozolomide as monotherapy leads to intracranial response percentages of 7%-9% in patients with brain metastases from a melanoma.
B: Boogerd, 2007 (21)
C: Agarwala, 2004 (20)

Germ cell tumours
Level 3
There are indications that, in patients with brain metastases derived from germ cell tumours, complete remission can be achieved with chemotherapy, possibly combined with surgery and/or radiotherapy.
C: Gremmer, 2008 (24);Gerl, 1996 (25);Evans, 1995 (35)

Combination therapy
Level 2
It is plausible that the addition of temozolomide to radiotherapy in patients with brain metastases does not lead to a longer survival.
B: Antonadou, 2002 (27);Verger, 2005 (28)

Level 2
It is plausible that the application of radiosensitisers combined with radiotherapy in patients with brain metastases does not lead to a longer survival or better intracranial response.
A2: Mehta, 2009 (34)
B: Suh, 2006 (33)

Systemic or medication-based therapy has a modest role in the treatment of patients with symptomatic brain metastases. The decision to treat patients depends, amongst other things, on the extensiveness of the extra- and intracranial disease, the KPS and neurological symptoms (see Whether or not treatment should be performed). The literature generally considers patients with non-resectable brain metastases.

The blood-brain barrier (BBB) has long been considered a limiting factor for therapeutic intracerebral concentrations of especially large and lipophobic medication. However, the BBB is regularly disturbed in the presence of brain metastases, as has been demonstrated by staining after contrast during imaging. Brain metastases therefore appear to respond in the same way to systemic therapy as metastases elsewhere in the body.

Medications that disturb the BBB such as mannitol appear to have a biological effect but have been insufficiently studied to be applied outside a trial context (Fortin, 2007 (1)).

No research has been conducted to evaluate whether corticosteroids given during systemic therapy strengthen the BBB, thereby preventing medication from reaching the metastases.

The choice of systemic treatment is directed by several factors:

  • the primary tumour and the associated corresponding sensitivity of the metastases to systemic therapy
  • the presence and growth of extracranial disease
  • (in)accessibility for surgery and radiotherapy
  • earlier treatment of the metastases

Since the choice of therapy depends on the characteristics of the primary tumour, the various treatment options are discussed per tumour type.

Non-small cell lung carcinoma (NSCLC)

In a small study, 48 not previously treated patients with synchronous brain metastases from NSCLC who were asymptomatic after dexamethasone, were randomised between primary treatment with chemotherapy (gemcitabine and vinorelbine in a 3-weekly schedule) followed by WBRT versus WBRT followed by chemotherapy (Lee, 2008 (2)). The study stratified for performance status and number of brain metastases (> or <3). There was no statistically significant difference in intracranial response between both groups (28% for chemotherapy first and 39% for WBRT first), although 4 of the 21 patients in the group receiving WBRT first were not given follow-up treatment with chemotherapy because of clinical decline or death. There was no difference in progression-free survival (3.6 versus 4.4 months, chemotherapy first versus WBRT first) or in survival (median survival 9.1 versus 9.9 months). Neurological functioning worsened in both groups. The intracranial response had a strong correlation with the extracranial response.

In another different prospective study of 171 patients (Robinet, 2001 (3)), patients with symptomatic brain metastases from NSCLC who had not been treated before were randomised between synchronous treatment with chemotherapy (cisplatin/vinorelbine)+WBRT and chemotherapy followed by WBRT in the case of non-response after 2, 4 or 6 courses of chemotherapy. Eventually, 57/86 (66%) of the patients in the delayed WBRT group were irradiated. No difference was found in intracranial response (33% and 27% respectively) and extracranial response (20% and 21% respectively), median survival (21 and 24 weeks) and treatment-related toxicity.

No data are available on the treatment of symptomatic brain metastases with systemic therapy without the addition of WBRT as mentioned in the treatment protocol.

Other studies on patients with brain metastases from NSCLC treated with chemotherapy involved metastases that were asymptomatic (see Asymptomatic brain metastases).
Patients who present with limited intracranial and extracranial disease may undergo aggressive treatment with curative intent as outlined in Synchronous brain metastases.

Small cell lung carcinoma (SCLC)
Patients who initially present with brain metastases have an extensive disease (stage IV) SCLC. Systemic chemotherapy is often commenced as first-line treatment. Some smaller studies report intracranial response percentages of 27% in asymptomatic patients (Seute, 2006 (4)) to 79% in those with symptomatic brain metastases (Kantarjian, 1984 (5);Lee, 1989 (6);Humblet, 1989 (7);Twelves, 1990 (8);Kristjansen, 1993 (9);Tummarello, 1998 (10)). However, these studies were non-controlled and therefore highly sensitive to selection bias, and it is therefore unlikely that the abovementioned percentages are achievable in daily practice.

In a prospective randomised study of 120 patients presenting with brain metastases from SCLC who had been previously treated for SCLC (and who have therefore previously received chemotherapy, i.e. in 72% of cases) (Postmus, 2000 (11)), randomisation took place between direct WBRT and chemotherapy (teniposide) versus delayed WBRT after initial treatment with chemotherapy. Direct WBRT after chemotherapy resulted in a better intracranial response (57 vs 22%) and prolonged time to progression. There was no significant difference in extracranial response (33 vs 20 %) and also no significant difference in survival (median survival was approximately 3 months in both groups).

See the guideline on SCLC for systemic treatment (link) and for the indications for PCI (link).

Breast carcinoma
Small studies in which patients with brain metastases from breast carcinoma were primarily treated with systemic therapy reported an intracranial chance of response of 30-60% (Boogerd, 1992 (12);Colleoni, 1997 (13);Franciosi, 1999 (14)); however, the chemotherapy schedules used in these studies have become obsolete. Although no comparative studies are available, intracranial response percentages appear comparable with to those of extracranial metastases. There is insufficient literature to formulate recommendations regarding the choice of specific chemotherapeutic agents that easily pass the BBB. In practice, the choice for systemic therapy is primarily based on the patient's specific situation and on earlier treatment regimes.

There are no comparative studies available that compare systemic therapy with other treatment modalities in patients with brain metastases from breast carcinoma.

There is a modest role for lapatinib in patients with brain metastases from HER2/neu positive breast carcinoma that are progressive after earlier radiotherapy (Lin, 2008_JCO (15)). The chance of response improves somewhat when capecitabine is added to lapatinib (20% intracranial response in a selected population) (Lin, 2009 (16)). See also Recurrence of brain metastases.

Multiple studies have demonstrated an increase in overall survival and probably also progression-free survival among patients with brain metastases from HER2/neu positive breast carcinoma if treatment with trastuzumab (and chemotherapy) is continued after local treatment (Church, 2008 (17);Bartsch, 2007 (18)).

Brain metastases are relatively common in patients with melanoma (21% reported in patients with stage IV melanoma) (Fogarty, 2006 (19)).
Treatment with temozolomide was evaluated in a phase-2 study. An intracranial response percentage of 7% has been reported in patients with brain metastases who did not require direct radiotherapy and who were not pretreated (Agarwala, 2004 (20)). In a retrospective analysis of patients with a melanoma who were treated with temozolomide within a trial context, patients with small (<2 cm) brain metastases were identified (Boogerd, 2007 (21)), and an objective intracranial response of 9% was reported for this group.

Germ cell tumours
Both standard and rescue chemotherapy may be curative for the treatment of germ cell tumours that have metastasised to the brain. In a German series comprising 132 patients with metastatic germ cell tumours that were treated within a trial context with high dose chemotherapy, either in or not in combination with radiotherapy and surgery, 22 patients were found to have brain metastases (of which 32% were symptomatic). Eight of the 22 patients achieved CR (follow-up 4-20 years), 7 of the 8 patients also underwent a craniotomy and WBRT. The reported 2-year disease-free survival of 77% in patients with brain metastases is comparable to the disease-free survival of the series' patients who do not have brain metastases (Kollmannsberger, 2000 (22)). These results were confirmed in other series (Bokemeyer, 1997 (23);Gremmer, 2008 (24)).

The treatment of brain metastases consists of standard platinum-containing chemotherapy, preceded with resection in the case of large and/or haemorrhagic brain metastases. In the case of incomplete intracranial remission after chemotherapy, additional local therapy is administered (WBRT and/or SRS and/or neurosurgical resection) (Bokemeyer, 1997 (23);Gerl, 1996 (25);Gremmer, 2008 (24);Kollmannsberger, 2000 (22);Nonomura, 2009 (26)).

The treatment is curative in nature and the possible long-term neurocognitive damage caused by irradiation must therefore be taken into account in deciding over the appropriate radiotherapy schedule.

Other tumour types
Aside from case-reports, there are no data on the treatment of brain metastases from other tumours than those outlined above. The decision whether or not to provide systemic treatment should therefore be made on an individual basis.

Combination therapy
In the primary treatment of different tumour types (oesophagus, rectum, anus, cervix, head-neck, primary brain glioma), the standard treatment is radiotherapy combined with systemic therapy (chemotherapy and other radiosensitisers). Combination therapy allows for a better response and survival of the primary tumour.

Given the positive effects of the addition of temozolomide to the radiotherapy of primary brain tumours, multiple phase 2 studies have also been conducted on the combination of radiotherapy with temozolomide for patients with brain metastases. This specifically concerns patients with a breast carcinoma, SCLC or NSCLC and a small percentage of remaining primary tumour types. Results of these studies show an acceptable toxicity profile with high response percentages of the combined treatment between 33% and 96%. There is no demonstrated effect on survival (Antonadou, 2002 (27);Verger, 2005 (28)). In a randomised phase 2 study (Antonadou, 2002 (27)), a better objective response (CR and PR) was observed with patients receiving combined temozolomide and WBRT compared to patients only treated with WBRT (96% vs 67%). This difference was not significant given the small patient number. In another randomised phase 2 study (Verger, 2005 (28)), response percentages for WBRT with or without temozolomide were comparable (33%), but a higher percentage persistent remission was seen after 90 days (WBRT with and without temozolomide 17% versus 5%).

The combination of radiotherapy with other chemotherapeutic agents has also been studied, but these studies have been either too small or were non-randomised (Cassier, 2008 (29);Mornex, 2003 (30);Neuhaus, 2009 (31);Guerrieri, 2004 (32)). A definitive conclusion about the effectiveness of these treatments can therefore not be drawn.

A large prospective study with 515 patients with brain metastases from different tumour types randomised patients between WBRT and WBRT with efraproxiral, a haemoglobin analogue. With a median survival of 6.0 (efraproxiral and WBRT) versus 4.4 months (WBRT only), there was no significant difference between the two groups (p=0.07) (Suh, 2006 (33)). A prospective randomised study with WBRT +/- motexafin gadolinium in patients with brain metastases from NSCLC also showed no difference in survival. A non-significant difference in time to neurological decline was observed (10.0 versus 15.4 months, p=0.122), particularly in patients who had a short interval between the treatment with motexafin gadolinium and WBRT (Mehta, 2009 (34)).

Click here for the evidence tables.

  1. 1 - Fortin D, Gendron C, Boudrias M, Garant MP. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007 Feb 15;109(4):751-60.
  2. 2 - Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer 2008 Jul 1;113(1):143-9.
  3. 3 - Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001 Jan;12(1):59-67.
  4. 4 - Seute T, Leffers P, Wilmink JT, ten Velde GP, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006 May 1;24(13):2079-83.
  5. 5 - Kantarjian H, Farha PA, Spitzer G, Murphy WK, Valdivieso M. Systemic combination chemotherapy as primary treatment of brain metastasis from lung cancer. South Med J 1984 Apr;77(4):426-30.
  6. 6 - Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989 Jul;7(7):916-22.
  7. 7 - Humblet Y, Weynants P, Bosly A, Majois F, Duprez P, Francis C, et al. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group. Med Oncol Tumor Pharmacother 1989;6(3):207-12.
  8. 8 - Twelves CJ, Souhami RL, Harper PG, Ash CM, Spiro SG, Earl HM, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990 Jan;61(1):147-50.
  9. 9 - Kristjansen PE, Soelberg SP, Skov HM, Hansen HH. Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 1993 Aug;4(7):579-83.
  10. 10 - Tummarello D, Lippe P, Bracci R, Mari D, Monterubbianesi MC, Battelli N. First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer. Oncol Rep 1998 Jul;5(4):897-900.
  11. 11 - Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000 Oct 1;18(19):3400-8.
  12. 12 - Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992 Feb 15;69(4):972-80.
  13. 13 - Colleoni M, Graiff C, Nelli P, Vicario G, Sgarbossa G, Pancheri F, et al. Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Am J Clin Oncol 1997 Jun;20(3):303-7.
  14. 14 - Franciosi V, Cocconi G, Michiara M, Di CF, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999 Apr 1;85(7):1599-605.
  15. 15 - Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008 Apr 20;26(12):1993-9.
  16. 16 - Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009 Feb 15;15(4):1452-9.
  17. 17 - Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008 Jun;31(3):250-4.
  18. 18 - Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007 Dec;85(3):311-7.
  19. 19 - Fogarty GB, Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin Oncol (R Coll Radiol ) 2006 May;18(4):360-2.
  20. 20 - Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004 Jun 1;22(11):2101-7.
  21. 21 - Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 2007 Jan 15;109(2):306-12.
  22. 22 - Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, et al. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000 May;11(5):553-9.
  23. 23 - Bokemeyer C, Nowak P, Haupt A, Metzner B, Kohne H, Hartmann JT, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997 Apr;15(4):1449-54.
  24. 24 - Gremmer R, Schroder ML, Ten Huinink WW, Brandsma D, Boogerd W. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 2008 Dec;90(3):335-9.
  25. 25 - Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer 1996 Oct;74(8):1280-5.
  26. 26 - Nonomura N, Nagahara A, Oka D, Mukai M, Nakai Y, Nakayama M, et al. Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol 2009 Nov;16(11):887-93.
  27. 27 - Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002 Sep 1;20(17):3644-50.
  28. 28 - Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005 Jan 1;61(1):185-91.
  29. 29 - Cassier PA, Ray-Coquard I, Sunyach MP, Lancry L, Guastalla JP, Ferlay C, et al. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer 2008 Nov 1;113(9):2532-8.
  30. 30 - Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, et al. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer Radiother 2003 Feb;7(1):1-8.
  31. 31 - Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009 Jan 27;100(2):291-7.
  32. 32 - Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004 Oct;46(1):107-11.
  33. 33 - Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006 Jan 1;24(1):106-14.
  34. 34 - Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009 Mar 15;73(4):1069-76.
  35. 35 - Evans AC, Jr., Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez GC, Hammond CB. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995 Nov;59(2):226-30.

Authorization date and validity

Last review  : 01-07-2011

Last authorization  : 01-07-2011

The period of validity of the guideline (maximum of 5 years) is being monitored by IKNL. For various reasons, it may be necessary to revise the guideline earlier than intended. Sections of the guideline will be amended in the interim, when required.

Initiative and authorization

  • Nederlandse Vereniging voor Neurologie
Authorized by:
  • Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose
  • Nederlandse Vereniging voor Medische Oncologie
  • Nederlandse Vereniging voor Neurochirurgie
  • Nederlandse Vereniging voor Neurologie
  • Nederlandse Vereniging voor Radiotherapie en Oncologie
  • Verpleegkundigen en Verzorgenden Nederland
  • Nederlandse Vereniging voor Psychosociale Oncologie
  • Nederlands Instituut van Psychologen

Scope and target group


The guideline covers the processes of diagnosis, treatment, information provision and guidance of adult patients with metastases in the brain originating from solid tumours, thereby focusing on topical clinical problems encountered in daily practice. The guideline's recommendations aim to aid practitioners in their decision-making support when facing these problems. The recommendations are based on the highest available grade of scientific evidence and on consensus within the guideline development group. The guideline provides information on how the recommendations have been reached from the evidence.


The guideline may be used to provide information to patients and offers points of reference for transmural agreements or local protocols to facilitate implementation.


The guideline is intended for all professionals involved in the diagnostics, treatment and guidance of adult patients with brain metastases of solid tumours. These professionals include:

  • Primary specialists: neurologists, neurosurgeons, radiotherapists, medical oncologists, pulmonologists, (oncology) nurses, general practitioners, specialists (working) in palliative care
  • Supporting specialists: radiologists, pathologists
  • Healthcare providers specialised in psychosocial care: social workers, psychologists, psychiatrists and geriatric medicine specialists


Samenstelling werkgroep



mw. dr. J.M.M. Gijtenbeek, neuroloog, Universitair Medisch Centrum St Radboud, Nijmegen

Other members:

dr. L.V. Beerepoot, medisch oncoloog, St. Elisabeth Ziekenhuis, Tilburg

dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam

mw. S. Bossmann, nurse practitioner, Universitair Medisch Centrum St Radboud Nijmegen

mw. dr. M. van Dijk, internist-oncoloog, Maastricht Universitair Medisch Centrum, Maastricht

mw. dr. A.C. Dingemans, longarts, Maastricht Universitair Medisch Centrum, Maastricht

mw. dr. C. van Es, radiotherapeut-oncoloog, Utrecht Universitair Medisch Centrum, Utrecht, niet actief betrokken (is betrokken geweest bij het initiëren van de werkgroep maar kon vanwege onvoorziene omstandigheden niet aan de totstandkoming van de richtlijn meewerken)

dr. A. de Graeff, medisch oncoloog, Utrecht Universitair Medisch Centrum, Utrecht

dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Gamma Knife Centrum, Tilburg

dr. H.F.M. van der Heijden, longarts, Universitair Medisch Centrum St Radboud, Nijmegen

dr. M.A.A.M. Heesters, radiotherapeut-oncoloog Universitair Medisch Centrum Groningen, Groningen

dr. P.A. M. Hofman, neuroradioloog, Maastricht Universitair Medisch Centrum, Maastricht

dr. R.L.H. Jansen, medisch oncoloog, Maastricht Universitair Medisch Centrum, Maastricht, niet actief betrokken

drs. E. Kurt, neurochirurg, Medisch Centrum Alkmaar

dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam

mw. prof.dr. J.B. Prins, klinisch psycholoog, Universitair Medisch Centrum St Radboud, Nijmegen

drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden

drs. V.K.Y. Ho, epidemioloog/procesbegeleider, Integraal Kankercentrum Nederland (IKNL), locatie Utrecht

mw. M.L. van de Kar, ambtelijk secretaris, Landelijke Werkgroep Neuro-Oncologie (LWNO), Bussum

Ondersteuning methodologie

mw. dr. M. Brink, epidemioloog, IKNL, locatie Utrecht

drs. J.M. van der Zwan, MSc, epidemiologisch onderzoeker, IKNL, locatie Enschede


Leden werkgroep voorgaande revisie (2004)

dr. R.H. Boerman, neuroloog, Rijnstate Ziekenhuis, Arnhem (voorzitter)

dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam

mw. dr. W.M.H. Eijkenboom, radiotherapeut-oncoloog, Daniel den Hoed Kliniek, Rotterdam

dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Dr. Bernard Verbeeten Instituut, Tilburg

dr. R.L.H. Jansen, medisch oncoloog, Academisch Ziekenhuis Maastricht

dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam

prof.dr. C.J.A. Punt, inetrnist-oncoloog, Academisch Ziekenhuis Nijmegen

drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden

prof.dr. J.T. Wilmink, neuroradioloog, Academisch Ziekenhuis Maastricht

dr. J.G. Wolbers, neurochirurg, Academisch Ziekenhuis Dijkzigt, Rotterdam



Declaration of interest

All guideline working group members were asked to fill in a conflict of interest declaration, in which they stated ties with the medical industry at the start and completing the guideline process. An overview of these conflict of interest declarations can be found below. The remaining guideline working group members have declared that at this moment or in the last three years they have not performed any activities on invitation or with subsidy/sponsoring by the medical industry.





Dr. L.V. Beerepoot




consultatie / advisering




Dr. W. Boogerd




Dr. M. van Dijk

Schering Plough



Dr. A.C. Dingemans




Astra Zeneca



consultatie / advisering / wetenschappelijk onderzoek

consultatie / advisering

consultatie / advisering / wetenschappelijk onderzoek

consultatie / advisering / wetenschappelijk onderzoek




Dr. C.A. van Es




Dr. A. de Graeff




consultatie / advisering

consultatie / advisering


Dr. P.A.M. Hofman

Strijker NL B.V.

Medtronics Spinal

Bayer Health Care

Johnson & Johnson






Dr. H.F.M. van der Heijden

Astra Zeneca

Sanofi Aventis




consultatie / advisering

consultatie / advisering

consultatie / advisering / wetenschappelijk onderzoek







Dr. R.L.H. Jansen



Sanofi Aventis

Diverse firma's



wetenschappelijk onderzoek





Dr. F.J. Lagerwaard

Roche Nederland

Roche NL-longadviesraad

Brain Lab

Varian Medical Systems

wetenschappelijk onderzoek

consultatie / advisering







Method of development

evidence based


Considerations concerning the implementation of the guideline as well as the feasibility of recommendations have been taken into account as much as possible in drafting the revised guideline.


The guideline is summarised and may be consulted in its entirety on The guideline has been brought to the attention of members of the LWNO, hospitals in the Netherlands, oncology commissions, as well as the scientific and professional associations involved. To further stimulate awareness and implementation of the guideline, regional tumour working groups on neuro-oncology of IKNL were invited to discuss its recommendations.


Given the highly progressive and unfavourable course of the disease, the guideline development group decided not to develop care indicators to measure the level of guideline implementation.